Pla2g2a is considered to be a tumour suppressor independent of the Wnt/β-catenin signalling pathway, and intraluminal secretion of Pla2g2a is a host defence mechanism during the active phase of ulcerative colitis53. Here, PLA2G2A is linked to neoplasm.